IAI FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Umemura, M.
Right arrow Articles by Yoshikai, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Umemura, M.
Right arrow Articles by Yoshikai, Y.

 Previous Article  |  Next Article 

Infection and Immunity, October 2003, p. 6045-6048, Vol. 71, No. 10
0019-9567/03/$08.00+0     DOI: 10.1128/IAI.71.10.6045-6048.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Interleukin-15 as an Immune Adjuvant To Increase the Efficacy of Mycobacterium bovis Bacillus Calmette-Guérin Vaccination

Masayuki Umemura,1 Hitoshi Nishimura,2* Kimika Saito,2 Toshiki Yajima,2 Goro Matsuzaki,1 Satoru Mizuno,3 Isamu Sugawara,3 and Yasunobu Yoshikai2

Molecular Microbiology Group, Center of Molecular Biosciences, University of the Ryukyus, Okinawa 903-0213,1 Division of Host Defense, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582 ,2 Department of Molecular Pathology, the Research Institute of Tuberculosis, Kiyose 204-0022, Japan3

Received 17 March 2003/ Returned for modification 7 May 2003/ Accepted 30 June 2003

Interleukin-15 (IL-15) transgenic mice which had been inoculated with Mycobacterium bovis bacillus Calmette-Guérin (BCG) 24 weeks previously showed resistance against airborne infection with Mycobacterium tuberculosis H37Rv accompanied by an increased CD8+-Tc1-cell response. IL-15 may be used as an immune adjuvant given with BCG vaccination to enhance its biologic efficacy.


* Corresponding author. Mailing address: Division of Host Defense, Medical Institute of Bioregulation, Kyushu University 3-1-1, Maidashi, Higashiku, Fukuoka 812-8582, Japan. Phone: 81-92-642-6962. Fax: 81-92-642-6973. E-mail: nishihit{at}bioreg.kyushu-u.ac.jp.

Editor: J. D. Clements


Infection and Immunity, October 2003, p. 6045-6048, Vol. 71, No. 10
0019-9567/03/$08.00+0     DOI: 10.1128/IAI.71.10.6045-6048.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals

Copyright © 2003 by the American Society for Microbiology. All rights reserved.